EGFR and non-small cell lung carcinoma: The ADJUVANT study demonstrated that adjuvant gefitinib resulted in a significantly longer disease-free survival (DFS) than cisplatin plus vinorelbine in patients with completely resected stage II–IIIA EGFR-mutant NSCLC [10].